Maze Therapeutics, Inc.
Maze Therapeutics, Inc.（MAZE）内幕交易
基于 SEC Form 4 的买入/卖出笔数、买卖比与情绪标签；可在本季度与近12个月之间切换；下方为季度图与交易明细。
SEC EDGAR · FMP · MAZE · 截至 2026年6月8日
活动摘要
买入笔数
0
P-Purchase only
卖出笔数
46
近12个月
买卖比
0.00
Buy/Sell (by trades)
整体情绪
Maze Therapeutics, Inc.内部人在过去近12个月主要在卖出股份，卖出行为通常由预设的Rule 10b5-1计划驱动，不一定代表对公司的负面看法。
▸ 数据来源：SEC EDGAR · Form 3 & 4 · 买入仅计P-Purchase · 卖出仅计S-Sale
截至 2026年6月8日
MAZE 季度内部人买卖趋势
MAZE 内幕交易卖出 · MAZE 内幕交易买入 · 季度活动
Mobile shows last 4Q · Desktop shows full 8Q
▸ 数据来源：SEC EDGAR · Form 3 & 4 · 最近8季度
As of Jun 8, 2026
活跃内部人
近12个月交易最活跃 · MAZE CEO内幕交易
显示全部内部人 · 点击卡片过滤下方交易表
▸ 按reportingName聚合 · 近12月交易次数Top5 · 无额外API
近期内幕交易记录
MAZE 高管卖出股份 · MAZE 董事内幕交易 · SEC Form 4申报
横向滑动查看全部列
| 日期 | 内部人 | 类型 | 股数 | 总金额 | 申报 |
|---|---|---|---|---|---|
| Jun 1, 2026 | Coloma Jason V CEO · Director | Sale | 6,090 | $160K | Form 4 |
| Jun 1, 2026 | Coloma Jason V CEO · Director | Sale | 553 | $15K | Form 4 |
| Jun 1, 2026 | Bernstein Harold President, R&D & CMO | Option | 14,853 | $155K | Form 4 |
| Jun 1, 2026 | Bernstein Harold President, R&D & CMO | Sale | 13,253 | $339K | Form 4 |
| Jun 1, 2026 | Bernstein Harold President, R&D & CMO | Sale | 1,600 | $42K | Form 4 |
| May 29, 2026 | Dandekar Atul CSBO | Option | 7,500 | $78K | Form 4 |
| May 29, 2026 | Dandekar Atul CSBO | Sale | 7,500 | $198K | Form 4 |
| May 22, 2026 | Coloma Jason V CEO · Director | Sale | 4,504 | $117K | Form 4 |
| May 26, 2026 | Coloma Jason V CEO · Director | Sale | 25,582 | $666K | Form 4 |
| May 22, 2026 | Coloma Jason V CEO · Director | Sale | 2,478 | $64K | Form 4 |
| May 15, 2026 | Coloma Jason V CEO · Director | Sale | 1,822 | $47K | Form 4 |
| May 15, 2026 | Coloma Jason V CEO · Director | Sale | 116 | $3K | Form 4 |
| May 14, 2026 | Bernstein Harold President, R&D & CMO | Option | 15,000 | $156K | Form 4 |
| May 14, 2026 | Bernstein Harold President, R&D & CMO | Sale | 15,000 | $393K | Form 4 |
| May 4, 2026 | Dandekar Atul CSBO | Option | 5,985 | $62K | Form 4 |
| May 4, 2026 | Dandekar Atul CSBO | Option | 8,320 | $87K | Form 4 |
| May 4, 2026 | HOMCY CHARLES J Director | Gift | 7,422 | — | Form 4 |
| Apr 29, 2026 | Dandekar Atul CSBO | Option | 7,500 | $78K | Form 4 |
| Apr 29, 2026 | Dandekar Atul CSBO | Sale | 7,500 | $190K | Form 4 |
| Apr 1, 2026 | Bernstein Harold President, R&D & CMO | Option | 15,000 | $156K | Form 4 |
| Apr 1, 2026 | Bernstein Harold President, R&D & CMO | Sale | 11,352 | $332K | Form 4 |
| Apr 1, 2026 | Bernstein Harold President, R&D & CMO | Sale | 3,348 | $101K | Form 4 |
| Apr 1, 2026 | Bernstein Harold President, R&D & CMO | Sale | 300 | $9K | Form 4 |
| Apr 1, 2026 | Bachrodt Amy SVP, Finance | Option | 2,500 | $26K | Form 4 |
| Apr 1, 2026 | Bachrodt Amy SVP, Finance | Sale | 2,200 | $65K | Form 4 |
⚡ = 金额≥$100万 · Award/Option价格显示— · 仅Form4 · 仅普通股
▸ 数据来源：SEC EDGAR · Form 4 申报 · ⚡ = 金额≥$100万 · Award/Option 价格显示 —
关于 MAZE 内幕交易
MAZE 内幕交易
Maze Therapeutics, Inc.（MAZE）内幕交易数据来源于公司内部人（包括Bernstein Harold (President, R&D & CMO), Bachrodt Amy (SVP, Finance), Dandekar Atul (CSBO)）提交的SEC Form 4申报文件。过去12个月内，5位内部人向SEC提交了交易申报。MAZE内部人近期主要在卖出，这可能反映预设的10b5-1计划执行，而非方向性判断。
如需查看Maze Therapeutics, Inc.机构持仓比例和内部人持股百分比，请访问持仓（Ownership）标签页 → Ownership tab →
常见问题
MAZE 内幕交易 · 5个问题Maze Therapeutics, Inc.（MAZE）的内部人包括高管和董事，如Bernstein Harold (President, R&D & CMO), Bachrodt Amy (SVP, Finance), Dandekar Atul (CSBO)等。过去12个月内，5位内部人向SEC提交了Form 4交易申报。内部人须在交易日期后2个工作日内完成申报。
▸ 数据来源：FMP /stable/insider-trading/search · SEC EDGAR Form 3 & 4 · RSU归属不计入情绪 · As of Jun 8, 2026